DHA 1g + EPA 0.5g 12 Weeks: Meibomian Dysfunction -42%, Dry Eye -38% RCT
WELLNESS

DHA 1g + EPA 0.5g 12 Weeks: Meibomian Dysfunction -42%, Dry Eye -38% RCT

By Sophie · · Cornea 2025
KO | EN

Omega-3 DHA 1g + EPA 0.5g/day for 12 weeks reduced meibomian gland dysfunction (MGD) by 42%, dry eye symptoms (OSDI) by 38%, while improving tear film stability (TBUT) by 45%, reducing conjunctival redness by 32%, and blurred vision by 28% in 220 MGD patients, per a 2025 Cornea RCT. New standard matrix validation for the era of 35% dry eye in Korean women 50+.

The study followed 220 MGD patients (eyelid meibomian gland blockage + OSDI 23+) over 12 weeks in a randomized double-blind design. DHA 1,000mg + EPA 500mg/day (with EE vs TG form sub-analysis) or placebo. Results: meibum secretion score -42% (toward normal secretion), OSDI -38% (38 → 24), TBUT +45% (5s → 7.3s), Schirmer +28%, conjunctival redness -32%, blurred vision -28%, artificial tear use -45%. Side effects: fish oil burping 12%.

Meibomian Gland — The Hidden Organ in the Eyelid

What it is:

  • 25-40 secretory glands at the eyelid margin
  • Secretes meibum (lipid) → forms tear film outer layer
  • Blocks tear evaporation → maintains tear film stability
  • MGD = meibomian gland blockage and dysfunction

MGD mechanisms:

  • Aging, hormonal changes, digital devices, contact lenses
  • Gland blockage → reduced meibum secretion
  • Tear film outer layer defect → tear evaporation +50%
  • Chronic → meibomian gland atrophy (irreversible)

Korean statistics:

  • 18%+ diagnosed dry eye
  • 35% in women 50+
  • Post-menopausal estrogen decline → meibomian gland atrophy acceleration
  • Underdiagnosed, often treated only with artificial tears

DHA·EPA — Core of Meibum Lipid Composition

Mechanisms:

  • DHA: meibomian gland cell membrane fluidity ↑ → secretion recovery
  • EPA: anti-inflammatory (prostaglandin E3) → MGD inflammation block
  • Meibum lipid composition normalization (saturated → unsaturated ratio recovery)
  • Tear film outer layer stability ↑

Cumulative clinical data:

  • 2013 DREAM Study (NIH 535 patients) mixed results
  • 2018 meta-analysis 22 trials, OSDI -28% average
  • 2025 current RCT precision-targets EE/TG form + MGD
  • DHA:EPA 2:1 ratio outperforms 1:2

EE vs TG Form — TG Superior Absorption

The sub-analysis showed triglyceride (TG) form has +25% absorption vs ethyl ester (EE), with +12pp better OSDI improvement. Korean market is 90%+ EE form (cheaper). TG and rTG (re-esterified) forms cost 30-50% more but deliver superior efficacy.

Korean market guide:

  • TG/rTG form: NORDIC NATURALS, CARLSON, SOLGAR (50,000-150,000 KRW per 60 caps)
  • EE form: typical pharmacy omega-3 (15,000-40,000 KRW)
  • IFOS, MSC certification preferred (mercury, PCB verification)

Matrix — Saffron, Astaxanthin, Lutein Synergy

Dry eye matrix:

  • DHA 1g + EPA 0.5g/day (meibum, anti-inflammatory)
  • Astaxanthin 6mg/day (ocular antioxidant)
  • Saffron 30mg/day (retinal protection + tear film)
  • Vitamin D 2,000IU (meibomian gland differentiation)
  • Artificial tears (preservative-free) adjunct

Cautions

Safety matrix:

  • Anticoagulants (warfarin, DOAC, aspirin): physician evaluation (bleeding risk ↑)
  • Discontinue 2 weeks pre-surgery
  • Fish allergy: physician check
  • Rancid fish oil danger (acid value 5+ → discard, refrigerate)
  • 12+ weeks cumulative evaluation, with meibomian gland expression

MGD Integrated Treatment Matrix

Tier 1: Warm compress (Eye Mask 40°C) 5 min + eyelid pressure Tier 2: Artificial tears + omega-3 12 weeks Tier 3: Meibomian gland expression procedure (LipiFlow, iLux) Tier 4: Cyclosporine eye drops (chronic inflammation)

DHA·EPA forms the core of tier 1-2 matrix — recovering internal meibum lipid composition simultaneously with external treatment (compress).

Korean Market Status

Distribution:

  • TG/rTG omega-3: NORDIC NATURALS Ultimate Omega 80,000 KRW
  • DHA-dominant: NORDIC NATURALS DHA Xtra 70,000 KRW
  • IFOS certification essential (rancidity, heavy metals block)
  • 50+ post-menopausal women: matrix recommended

Global Dry Eye Market

US: TearLab, Sjögren’s Syndrome diagnostic standardization Europe: TFOS DEWS II (2017) guidelines recommend omega-3 grade II Korea: 50+ women target market growing post-2025

Spring 2026, DHA 1g + EPA 0.5g/day’s RCT validation of MGD meibum secretion -42% and TBUT +45% marks not just artificial tears but the starting point of internal lipid recovery — Korean women 50+ dry eye new standard.